None listed
Conditions
Interventions
None listed
Sponsors
AstraZenca
Eligibility
Inclusion criteria
Inclusion criteria: Patients diagnosed with incidental pulmonary nodules on CXR by qXR and confirmed by the radiologist at the site with nodule size =8 and =30 mm.
Exclusion criteria
Exclusion criteria: 1. Any medical or other contraindications for a CT scan 2. Nondigital CXR 3. CT scan is done more than 6 months after CXR 4. Patients with already diagnosed LC 5. The patients referred for an X-Ray for a suspicious LC 6. A patient who already participated in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. PPV of qXR-LNMS using a panel of radiologists assigning high-risk based on CT (done within 180 days from Xray) as the reference standard 2. NPV of qXR-LNMS using panel of radiologists assigning low-risk based on CT (done within 180days from Xray) as reference standardTimepoint: One year | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. PPV of qXR-LNMS using panel of radiologists assigning Lung-RADS4A based on CT as reference standard 2. PPV of qXR-LNMS using panel of radiologists assigning Lung-RADS4A based on CT as reference standard 3. To assess the correlation of qXR-LNMS and the Mayo clinic model 4. Clinically (2yr Follow Up) proven basedTimepoint: 1,2,3 - In one year. 4 - Three years. | — |
Countries
India, Mexico, Turkey
Contacts
Public ContactAkshay Mahale
Qure ai Technologies Private Limited
Outcome results
None listed